Hayden Royal’s Regeneron Pharmaceuticals REGN Stock Holding History

Hayden Royal’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	$512K	Sell	810 -17	-2%	-$10.5K	1.2%	15
2021 Q3	$500K	Sell	827 -35	-4%	-$21.7K	0.82%	27
2021 Q2	$481K	Sell	862 -15	-2%	-$7.6K	0.26%	87
2021 Q1	$415K	Buy	877 +132	+18%	+$64.3K	0.24%	99
2020 Q4	$360K	Buy	745 +12	+2%	+$6.48K	0.2%	120
2020 Q3	$410K	Sell	733 -2,158	-75%	-$1.31M	0.22%	113
2020 Q2	$1.8M	Buy	2,891 +2,257	+356%	+$1.28M	1.01%	21
2020 Q1	$310K	Buy	634 +64	+11%	+$26.4K	0.18%	136
2019 Q4	$227K	Buy	+570	New	+$192K	0.11%	190

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Hayden Royal's REGN Position: Q4 2021 in Review

Hayden Royal reduced its Regeneron Pharmaceuticals (REGN) stake by 2.1% in Q4 2021, selling an estimated $10.5K and leaving 810 shares worth $512K. The position accounts for 1.2% of the portfolio, ranked #15.

Hayden Royal first reported a position in REGN in Q4 2019 and has held it in 9 quarters since. The position peaked at $1.8M in Q2 2020. 1,079 funds tracked by Wall St. Rank hold REGN as of Q4 2021.

Hayden Royal held 810 shares of Regeneron Pharmaceuticals worth $512K as of Q4 2021.
Hayden Royal sold 17 Regeneron Pharmaceuticals shares in Q4 2021, an estimated $10.5K.
Regeneron Pharmaceuticals made up 1.2% of Hayden Royal's portfolio in Q4 2021, its #15 holding.
Hayden Royal first reported a position in Regeneron Pharmaceuticals in Q4 2019 and has held it in 9 quarters since.
Hayden Royal's Regeneron Pharmaceuticals position peaked at $1.8M in Q2 2020.
1,079 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2021.

Based on Hayden Royal's 13F filing for Q4 2021, filed 7 Feb 2022.